No Data
Why Viking Therapeutics Stock Plummeted by 24% in December
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)